1
|
Abstract
As the coronavirus disease (COVID-19) pandemic led to a global health crisis, there were limited treatment options and no prophylactic therapies for those exposed to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Convalescent plasma is quick to implement, potentially provides benefits, and has a good safety profile. The therapeutic potential of COVID-19 convalescent plasma (CCP) is likely mediated by antibodies through direct viral neutralization and Fc-dependent functions such as a phagocytosis, complement activation, and antibody-dependent cellular cytotoxicity. In the United States, CCP became one of the most common treatments with over half million units transfused despite limited efficacy data. More than a dozen randomized trials now demonstrate that CCP does not provide benefit for those with moderate to severe disease. However, similar to other passive antibody therapies, CCP is beneficial for early disease, when provided to elderly outpatients within 72 hours after symptom onset. Only high-titer CCP should be transfused. CCP should also be considered for immunosuppressed COVID-19 patients. CCP collected in proximity, by time and location, to the patient may be more beneficial due to SARS-CoV-2 variants. Additional randomized trial data are still accruing and should be incorporated with other trial data to optimize CCP indications.
Collapse
|
2
|
Li X, Zhang Y, Cheng F, Yu Y, Wang D. Metabolomics and Proteomics Reveal the Variation of Substances in Apheresis Platelets during Storage and Their Effects on Cancer Cell Proliferation. Transfus Med Hemother 2021; 48:79-90. [PMID: 33976608 PMCID: PMC8077496 DOI: 10.1159/000509944] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2019] [Accepted: 07/05/2020] [Indexed: 02/05/2023] Open
Abstract
INTRODUCTION Apheresis platelets (APs) are clinically and crucially important in the prevention and treatment of bleeding in patients with thrombocytopenia or cancer. However, few researchers have addressed the variation of supernatant metabolites and exosome proteins in APs during storage and their effects on cancer cell proliferation. OBJECTIVE This study was designed to explore the change rules of the metabolites and exosomal proteins of APs during storage and their effects on cancer cell proliferation. METHODS Metabolomics and proteomics were separately applied to analyze the variation of AP supernatant metabolites and exosomal proteins between freshly prepared day-0 and day-5 terminal-stored APs. Cell counting kit (CCK)-8 assay was performed to detect the effects of AP supernatants and exosomes on the proliferation of cancer cells. RESULTS We found that the supernatant metabolites and exosomal proteins in APs were significantly different on day 0 and day 5, and that many differential metabolites and exosomal proteins were associated with cancer characteristics. Furthermore, the day-5 AP supernatants had a greater inhibition of the proliferation of K562, HepG2, and HCT116 cancer cells, but the day-5 AP exosomes had no significant effect on the proliferation of these cancer cells. CONCLUSION The variant terminal-stored AP supernatants may inhibit the proliferation of cancer cells but the variant terminal AP exosomes have no effect on cancer cell proliferation.
Collapse
Affiliation(s)
- Xiaofei Li
- Department of Blood Transfusion, Chinese PLA General Hospital, Beijing, China
- Department of Blood Transfusion, Beijing Friendship Hospital, Capital Medical University, Beijing, China
| | - Yuan Zhang
- Department of Blood Transfusion, Beijing Friendship Hospital, Capital Medical University, Beijing, China
| | - Fu Cheng
- Department of Blood Transfusion, West China Hospital of Sichuan University, Chengdu, China
| | - Yang Yu
- Department of Blood Transfusion, Chinese PLA General Hospital, Beijing, China
| | - Deqing Wang
- Department of Blood Transfusion, Chinese PLA General Hospital, Beijing, China
| |
Collapse
|
3
|
Ngatchou W, Dreezen I, Kamdem F, Imandy G, Okalla C, Nkana A, Hacquebard JP, Origer P, Sango J, Lemogoum D, Mouliom S, Dzudie A, Ngote H, Hentchoya R, Metogo J, Germay O, Priso EB, Jansens JL, Luma H, Najdovski T. [Platelet collection in cardiac surgery: first experience with apheresis at the General Hospital in Douala]. Pan Afr Med J 2019; 31:41. [PMID: 30918567 PMCID: PMC6430850 DOI: 10.11604/pamj.2018.31.41.16571] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/16/2018] [Accepted: 09/15/2018] [Indexed: 11/11/2022] Open
Abstract
Cardiac surgery with extracorporeal circulation (ECC) is usually associated with the loss of a significant amount of blood. Adequate prophylaxis against blood loss and good perioperative hemostasis are known as processes limiting postoperative bleeding. Until now, the need for platelets in patients operated with extracorporeal circulation in our Department has been compensated for by total blood transfusion or platelet concentrates collected from several donors. We here report our first experience with platelet concentrate collection by apheresis at the General Hospital in Douala.
Collapse
Affiliation(s)
- William Ngatchou
- Département de Chirurgie, Faculté de Médecine et de Science Pharmaceutique de Douala, Cameroun
| | | | - Felicité Kamdem
- Service de Médecine et Spécialité Faculté de Médecine et Science Pharmaceutique de Douala, Cameroun.,Service de Médecine Hôpital Général de Douala, Cameroun
| | | | | | - Albert Nkana
- Service de Médecine et Spécialité Faculté de Médecine et Science Pharmaceutique de Douala, Cameroun
| | - Jean Pierre Hacquebard
- Service d'Anesthésie CHU St Pierre de Bruxelles, Université Libre de Bruxelles, Belgique
| | - Pierre Origer
- Service d'Anesthésie CHU St Pierre de Bruxelles, Université Libre de Bruxelles, Belgique
| | - Joseph Sango
- Département de Chirurgie, Faculté de Médecine et de Science Pharmaceutique de Douala, Cameroun
| | - Daniel Lemogoum
- Service de Médecine et Spécialité Faculté de Médecine et Science Pharmaceutique de Douala, Cameroun
| | | | | | - Henri Ngote
- Service de Médecine Hôpital Général de Douala, Cameroun
| | - Romuald Hentchoya
- Service d'Anesthésie Réanimation Hôpital Général de Douala, Cameroun
| | - Junette Metogo
- Département de Chirurgie, Faculté de Médecine et de Science Pharmaceutique de Douala, Cameroun.,Service d'Anesthésie Réanimation Hôpital Général de Douala, Cameroun
| | - Olivier Germay
- Service d'Anesthésie CHU St Pierre de Bruxelles, Université Libre de Bruxelles, Belgique
| | | | - Jean Luc Jansens
- Hôpital Erasme de Bruxelles, Université Libre de Bruxelles, Belgique
| | - Henry Luma
- Service de Médecine Hôpital Général de Douala, Cameroun.,Direction de Hôpital Général de Douala, Cameroun
| | | |
Collapse
|
4
|
Barro L, Drew VJ, Poda GG, Tagny CT, El-Ekiaby M, Owusu-Ofori S, Burnouf T. Blood transfusion in sub-Saharan Africa: understanding the missing gap and responding to present and future challenges. Vox Sang 2018; 113:726-736. [DOI: 10.1111/vox.12705] [Citation(s) in RCA: 20] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/03/2018] [Revised: 08/05/2018] [Accepted: 08/06/2018] [Indexed: 12/12/2022]
Affiliation(s)
- Lassina Barro
- International Ph.D. Program in Biomedical Engineering; College of Biomedical Engineering; Taipei Medical University; Taipei Taiwan
- Centre National de Transfusion Sanguine; Ouagadougou Burkina Faso
| | - Victor J. Drew
- International Ph.D. Program in Biomedical Engineering; College of Biomedical Engineering; Taipei Medical University; Taipei Taiwan
| | | | - Claude T. Tagny
- Faculty of Medicine and Biomedical Sciences; University of Yaounde I; Yaoundé Cameroon
| | | | | | - Thierry Burnouf
- International Ph.D. Program in Biomedical Engineering; College of Biomedical Engineering; Taipei Medical University; Taipei Taiwan
- Graduate Institute of Biomedical Materials and Tissue Engineering; College of Biomedical Engineering; Taipei Medical University; Taipei Taiwan
| |
Collapse
|
5
|
Drammeh B, De A, Bock N, Pathak S, Juma A, Kutaga R, Mahmoud M, Haule D, Sembucha S, Chang K, Nkya E, Kuehnert M, Marfin AA. Estimating Tanzania's National Met and Unmet Blood Demand From a Survey of a Representative Sample of Hospitals. Transfus Med Rev 2018; 32:36-42. [PMID: 28843515 PMCID: PMC5831253 DOI: 10.1016/j.tmrv.2017.07.004] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/03/2017] [Revised: 06/23/2017] [Accepted: 07/11/2017] [Indexed: 11/16/2022]
Abstract
Estimating blood demand to determine collection goals challenges many low-income countries. We sampled Tanzanian hospitals to estimate national blood demand. A representative sample based on probability proportional to size sampling of 42 of 273 (15%) Tanzanian transfusing hospitals was selected. Blood bank registers, patient medical records, and blood component disposition records were reviewed prospectively from June to September 2013 to determine the number of components requested and the number and proportion issued, not issued due to nonavailability, and not issued for other reasons. Data were estimated for an annual national estimate. Of an estimated 278 371 components requested in 2013, 6648 (2.4%) were not issued due to nonavailability, 34 591 (12.4%) were not issued for other reasons, and 244 535 (87.8%) were issued. Of these 278 371 components, 86 753 (31.2%) were requested by adult medical, 74 499 (26.8%) by pediatric medical, and 57 312 (20.6%) by obstetric units. In these 3 units, the proportion of units not issued due to nonavailability was 1.8%. Private (4.1%) and large (6%) hospitals had the largest proportion of units not issued because of nonavailability. Of 244 535 issued components, 91 690 (37.5%) were collected, tested, and issued from blood banks that are not part of the Tanzania National Blood Transfusion Services (TNBTS). Nearly 98% of blood component demand was met. However, a large portion of the blood supply for the hospitals came from non-TNBTS blood banks. TNBTS could increase availability of safe blood through assuring the quality of donor selection and donation testing at non-TNBTS blood banks.
Collapse
Affiliation(s)
- Bakary Drammeh
- HIV Prevention Branch, Division of Global HIV/AIDS, Centers for Disease Control and Prevention, Atlanta, GA.
| | - Anindya De
- Epidemiology and Strategic Information Branch, Division of Global HIV/AIDS, Centers for Disease Control and Prevention, Atlanta, GA
| | - Naomi Bock
- HIV Prevention Branch, Division of Global HIV/AIDS, Centers for Disease Control and Prevention, Atlanta, GA
| | | | - Abdu Juma
- Tanzania National Blood Transfusion Services, Ministry of Health and Social Welfare, Dar es Salaam, Tanzania
| | - Regina Kutaga
- US Centers for Disease Control and Prevention, Dar es Salaam, Tanzania
| | - Mwanakheir Mahmoud
- Zanzibar National Blood Transfusion Services, Ministry of Health Zanzibar, Zanzibar
| | - Dunstan Haule
- Tanzania National Blood Transfusion Services, Ministry of Health and Social Welfare, Dar es Salaam, Tanzania
| | - Senga Sembucha
- Field Epidemiology and Laboratory Training Program, US Centers for Disease Control and Prevention, Dar es Salaam, Tanzania
| | - Karen Chang
- Allan Rosenfield Global Health Fellow, American Schools of Public Health/Centers for Disease Control and Prevention, Atlanta, GA
| | - Efespa Nkya
- Tanzania National Blood Transfusion Services, Ministry of Health and Social Welfare, Dar es Salaam, Tanzania
| | - Matthew Kuehnert
- Office of Blood, Organ, and Other Tissue Safety, Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, GA
| | - Anthony A Marfin
- HIV Prevention Branch, Division of Global HIV/AIDS, Centers for Disease Control and Prevention, Atlanta, GA; PATH, Seattle, WA
| |
Collapse
|
6
|
Thiele T, Alt-Mayer T, Greinacher A, Bux J. Implications of a switch to a 100% apheresis platelet supply for patients and for blood donors: a risk benefit analysis. Vox Sang 2016; 111:350-356. [PMID: 27432635 DOI: 10.1111/vox.12433] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/27/2016] [Revised: 06/09/2016] [Accepted: 06/09/2016] [Indexed: 11/28/2022]
Abstract
BACKGROUND A 100% apheresis platelet supply is considered to increase transfusion safety by lowering donor exposures for transfusion recipients. We performed a risk benefit analysis to contrast the reduction of donor exposures and the risk of contaminated blood products in the nation-wide inventory with the donor risks associated with a switch to a 100% apheresis platelet supply in Germany. METHODS Donor exposures and the number of contaminated blood products resulting from HIV-like, HBV-like, HCV-like pathogens and two theoretical agents with infection rates of 10 and 1000 in 100 000, respectively, were calculated for a 100% apheresis platelet supply in Germany based on the 2006-2012 hemovigilance reports. These numbers were compared with the current mixed platelet supply of pooled and apheresis platelets. Moreover, additional donation time and apheresis donor complications resulting from a 100% apheresis platelet supply were estimated. RESULTS Per million total blood products (red cells, platelets, fresh frozen plasma), a 100% apheresis platelet supply would reduce donor exposures by 87 100 and the number of contaminated blood products ranging from 0·8 to 871·1. On the other hand, this requires additional 29 478 apheresis donations, 3·4 years additional donor time, and would be associated with 58 additional donor complications, respectively. CONCLUSIONS A 100% apheresis platelet supply would reduce donor exposures and the number of contaminated blood products in the inventory, but would increase apheresis complications in donors. Potential risks for patients must be carefully weighed against the risks for donors, dependent on the specific pathogen scenario.
Collapse
Affiliation(s)
- T Thiele
- Institute for Immunology and Transfusion Medicine, Universitätsmedizin Greifswald, Greifswald, Germany
| | - T Alt-Mayer
- German Red Cross Blood Service West, Bad Kreuznach, Germany
| | - A Greinacher
- Institute for Immunology and Transfusion Medicine, Universitätsmedizin Greifswald, Greifswald, Germany
| | - J Bux
- Ruhr University, Bochum, Germany
| |
Collapse
|